Ęterna Zentaris Company Description
Ęterna Zentaris, formerly Ęterna Laboratories, knows seriously ill patients can't wait an eternity for new drugs, so the firm is working to take lead drug candidates through trials and to approvals as quickly as possible. The company's pipeline got a boost from the purchase of Zentaris, which has two drugs on the market and a dozen others in development for the treatment of cancer and endocrinology disorders. The firm's flagship candidate, Cetrorelix (intended for in vitro fertilization and to treat patients with benign enlargement of the prostate and endometriosis), is in late-stage trials. The product was launched in Japan under the brand name Cetrotide.
View the Comprehensive Company Description for Ęterna Zentaris
The Company Description provides a historical perspective of Ęterna Zentaris's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Ęterna Zentaris's evolution in the marketplace.
